- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00533897
Phase IIIB Subcutaneous Missed Dose Study
22 aprile 2015 aggiornato da: Bristol-Myers Squibb
A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Immunogenicity and Safety of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis
The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
270
Fase
- Fase 3
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Cordoba, Argentina, 5000
- Local Institution
-
Santa Fe, Argentina, 3000
- Local Institution
-
-
Buenos Aires
-
Capital Federal, Buenos Aires, Argentina, 1015
- Local Institution
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, 2000
- Local Institution
-
-
-
-
Quebec
-
Trois-Rivieres, Quebec, Canada, G8Z 1Y2
- Local Institution
-
-
-
-
Distrito Federal
-
Mexico City, Distrito Federal, Messico, 06726
- Local Institution
-
-
Estado De Mexico
-
Metepec, Estado De Mexico, Messico, 52140
- Local Institution
-
-
Guanajuato
-
Leon, Guanajuato, Messico, 37520
- Local Institution
-
-
Yucatan
-
Merida, Yucatan, Messico, 97000
- Local Institution
-
-
-
-
California
-
Los Angeles, California, Stati Uniti, 90048
- Wallace Rheumatic Study Center
-
-
Connecticut
-
Trumbull, Connecticut, Stati Uniti, 06611
- New England Research Associates, LLC
-
-
Florida
-
Sarasota, Florida, Stati Uniti, 34239
- Sarasota Arthritis Research Center
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46227
- Diagnostic Rheumatology And Research,Pc
-
-
Maryland
-
Cumberland, Maryland, Stati Uniti, 21502
- Klein And Associates, M.D., Pa
-
-
Massachusetts
-
Worcester, Massachusetts, Stati Uniti, 01610
- Clinical Pharmacology Study Group
-
-
Minnesota
-
Eagan, Minnesota, Stati Uniti, 55121
- St. Paul Rheumatology, P.A.
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87102
- Albuquerque Clinical Trials, Inc.
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Stati Uniti, 18015
- East Penn Rheumatology Associates
-
Duncansville, Pennsylvania, Stati Uniti, 16635
- Altoona Center for Clinical Research
-
Erie, Pennsylvania, Stati Uniti, 16508
- Center For Assessment And Research Of Erie
-
-
South Carolina
-
Columbia, South Carolina, Stati Uniti, 29204
- Columbia Arthritis Center
-
-
West Virginia
-
Clarksburg, West Virginia, Stati Uniti, 26301
- Mountain State Clinical Research
-
-
-
-
Free State
-
Bloemfontein, Free State, Sud Africa, 9317
- Local Institution
-
-
Gauteng
-
Muckleneuk, Gauteng, Sud Africa, 0002
- Local Institution
-
Pretoria, Gauteng, Sud Africa, 0084
- Local Institution
-
-
Kwa Zulu Natal
-
Berea, Kwa Zulu Natal, Sud Africa, 4001
- Local Institution
-
-
Western Cape
-
Panorama, Western Cape, Sud Africa, 7500
- Local Institution
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Clinical diagnosis of Rheumatoid Arthritis
- Disease Activity Score (DAS)28-C-Reactive Protein (CRP) score ≥ 3.2 and ≤5.1
- On background methotrexate at least 3 months (≥10mg weekly)
- Must be able to self injection or allow a care giver to do it for them
- Discontinue all Biologics and Disease-Modifying Anti-rheumatic Drugs (DMARDs) except for methotrexate
Exclusion Criteria:
- Participants who had prior exposure to abatacept or CTLA-4 Ig
- Received treatment with rituximab.
- Participants who have received treatment with leflunomide within 1 year of screening
- Participants who have received treatment with immunoadsorption columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore placebo: Placebo
|
Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
|
Sperimentale: Abatacept
|
Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Double-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 169
Lasso di tempo: Day 169
|
Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using an enzyme-linked immunosorbent assay (ELISA).
Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
|
Day 169
|
Re-introduction (RI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Groups
Lasso di tempo: Day 253 (short term)
|
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA.
Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
|
Day 253 (short term)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Placebo Group
Lasso di tempo: Day 253 (short term)
|
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA.
Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
|
Day 253 (short term)
|
Lead-in (LI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time
Lasso di tempo: For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug
|
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA.
Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
|
For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug
|
LI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by Electrochemiluminescence (ECL) Over Time
Lasso di tempo: For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug
|
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity.
Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule).
Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1.
Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
|
For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug
|
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time
Lasso di tempo: Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period
|
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA.
Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
Samples were obtained during treatment (TRT) visits.
|
Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period
|
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Post Visits
Lasso di tempo: Day 22 after last dose of drug to Day 85 after last dose of drug
|
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA.
Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
|
Day 22 after last dose of drug to Day 85 after last dose of drug
|
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time
Lasso di tempo: Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period
|
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity.
Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule).
Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1.
Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
|
Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period
|
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL At Post Visits
Lasso di tempo: Day 22 after last dose of drug to Day 85 after last dose of drug
|
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity.
Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule).
Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1.
Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
|
Day 22 after last dose of drug to Day 85 after last dose of drug
|
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time by DBW Treatment Group
Lasso di tempo: For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug
|
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA.
Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
|
For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug
|
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time by DBW Treatment Group
Lasso di tempo: For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug
|
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity.
Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule).
Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1.
Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
|
For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug
|
Short Term (ST); Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ELISA Antibody Responses by DBW Treatment Groups
Lasso di tempo: For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug
|
Serum samples from Abatacept-treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA.
Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
ST was defined as the LI Period, the DBW Period, and the RI Period (Days 1-253).
|
For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug
|
Short Term: Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ECL Antibody Responses by DBW Treatment Groups
Lasso di tempo: For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug
|
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity.
Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule).
Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1.
Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
|
For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug
|
Short Term: Mean Change in Disease Activity Score (DAS) 28 (Using C-Reactive Protein [CRP]) From Baseline Over Time by DBW Treatment Groups
Lasso di tempo: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
|
The DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale.
DAS28 has numeric thresholds defining high disease activity (> 5.1), low disease activity (≤ 3.2) and remission (< 2.6).
Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
|
Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
|
Short Term: Percentage of Participants Achieving Clinically Meaningful Improvement (CMI) in DAS 28 (CRP), Low Disease Activity (LDAS), or Clinical Remission Over Time by DBW Treatment Groups
Lasso di tempo: Days 85, 169, and 253 (short term)
|
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale.
DAS28 has numeric thresholds defining high disease activity (> 5.1), low disease activity (≤ 3.2) and remission (< 2.6).
Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
|
Days 85, 169, and 253 (short term)
|
Short Term; Mean Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline Over Time by DBW Treatment Groups
Lasso di tempo: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
|
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities.
The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do.
Higher scores= greater dysfunction.
A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered.
Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.
|
Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
|
Short Term; Percentage of Participants With HAQ-DI Response Over Time by DBW Treatment Groups
Lasso di tempo: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
|
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities.
The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do.
Higher scores= greater dysfunction.
A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered.
Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.
|
Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
|
LI; Mean Change in DAS 28 (CRP) From Baseline Over Time
Lasso di tempo: Days 1 (Baseline), 15, 29, 57, 78, 85
|
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale.
DAS28 has numeric thresholds defining high disease activity (> 5.1), low disease activity (≤ 3.2) and remission (< 2.6).
Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
|
Days 1 (Baseline), 15, 29, 57, 78, 85
|
LI; Percentage of Participants With Clinically Meaningful Improvement in DAS (CRP) Over Time
Lasso di tempo: Days 15, 29, 57, 78, 85
|
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale.
DAS28 has numeric thresholds defining high disease activity (> 5.1), low disease activity (≤ 3.2) and remission (< 2.6).
Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
|
Days 15, 29, 57, 78, 85
|
DBW Period; Mean Change in DAS 28 (CRP) From DBW Period Baseline (Day 85) Over Time
Lasso di tempo: Days 85 (Period 2 Baseline), 113, 141, and 169
|
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale.
DAS28 has numeric thresholds defining high disease activity (> 5.1), low disease activity (≤ 3.2) and remission (< 2.6).
Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
|
Days 85 (Period 2 Baseline), 113, 141, and 169
|
DBW Period; Percentage of Participants With Rheumatoid Arthritis (RA) Flare Over Time
Lasso di tempo: Days 85, 113, 141, and 169
|
A participant had an RA flare if at least 2 of the following criteria were met:
|
Days 85, 113, 141, and 169
|
RI Period; Mean Change in DAS 28 (CRP) From RI Period Baseline (Day 169) Over Time
Lasso di tempo: Days 169 (Period III Baseline), 197, 225, and 253
|
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale.
DAS28 has numeric thresholds defining high disease activity (> 5.1), low disease activity (≤ 3.2) and remission (< 2.6).
Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
|
Days 169 (Period III Baseline), 197, 225, and 253
|
LI; Number of Participants With Deaths, Serious Adverse Events (SAEs), SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation
Lasso di tempo: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment.
SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
|
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
LI Period; Number of Participants With AEs of Special Interest
Lasso di tempo: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
|
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
LI; Number of Participants With Hematology Values Meeting the Marked Abnormality (MA) Criteria
Lasso di tempo: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL).
Marked abnormality criteria are: Hemoglobin (HGB): >3 g/dL decrease from BL; Hematocrit: <0.75 * BL; Erythrocytes: <0.75 * BL; Platelets (PLT): <0.67 * LLN/>1.5 * ULN, or if BL < LLN then use <0.5 * BL and <100,000 mm^3; Leukocytes: <0.75 * LLN/ >1.25 * ULN, or if BL<LLN then use <0.8 * BL or >ULN, or if BL>ULN then use >1.2 * BL or <LLN; neutrophils+bands: <1.0 * 10^3 cells/ microliter (uL); eosinophils: >0.750 * 10^3 cells/uL; basophils: > 400 mm^3; monocytes: >2000 mm^3; lymphocytes: <0.750 * 10^3 cells/uL/ >7.50 * 10^3 cells/uL.
|
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
LI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
Marked abnormality criteria: Alkaline phosphatase (ALP): >2* ULN, or if BL>ULN then use >3* BL; aspartate aminotransferase (AST): >3* ULN, or if BL>ULN then use >4* BL; alanine aminotransferase (ALT): >3* ULN, or if BL>ULN then use >4* BL; G-Glutamyl transferase (GGT): >2* ULN, or if BL>ULN then use >3* BL; Bilirubin: >2* ULN, or if BL>ULN then use >4* BL; blood urea nitrogen (BUN): >2* BL; creatinine: >1.5* BL
|
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
LI; Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
Marked abnormality criteria: Sodium (Na): <0.95*LLN/ >1.05*ULN, or if BL<LLN then use <0.95*
BL or >ULN, or if BL>ULN then use>1.05*
BL or <LLN; potassium (K): <0.9* LLN/>1.1*ULN, or if BL<LLN then use <0.9*
BL or >ULN, or if BL>ULN then use>1.1*
BL or <LLN; (Cl): <0.9* LLN/>1.1*
ULN, or if BL<LLN then use <0.9*
BL or >ULN, or if BL>ULN then use>1.1*
BL or <LLN; calcium (Ca): <0.8* LLN/>1.2*
ULN, or if BL<LLN then use <0.75*
BL or >ULN, or if BL>ULN then use>1.25*
BL or <LLN; phosphorous (P): <0.75* LLN/ >1.25* ULN, or if BL<LLN then use 0.67* BL or >ULN, or if BL>ULN then use>1.33*
BL or <LLN
|
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
LI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
MA criteria: serum glucose (Glu): <65 mg/dL/>220 mg/dL;fasting serum Glu: <0.8* LLN/>1.5*upper
limits of normal (ULN),or if BL< lower limits of normal (LLN) then use 0.8*BL or > upper limits of normal (ULN),or if BL>ULN then use >2.0*BL or <LLN;total protein: <0.9*LLN/>1.1*ULN,or
if BL<LLN then use <0.9*BL or >ULN,or if BL>UNL then use >1.1*BL or <LLN; albumin: <0.9*LLN,or if BL<LLN then use <0.75 BL;uric acid: >1.5*ULN,or if BL>ULN then use >2*BL.
Urinalysis: Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells (RBCs), White Blood Cells (WBCs):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
|
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
|
LI Period; Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Lasso di tempo: Days 1, 15, 29, 57, 78, and 85
|
Blood pressure was taken in participants while seated and measured in millimeters of mercury (mmHg).
Pressures were assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept.
Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
|
Days 1, 15, 29, 57, 78, and 85
|
LI Period; Mean Heart Rate (HR)
Lasso di tempo: Days 1, 15, 29, 57, 78, and 85
|
Heart rate was taken in participants while seated and measured in beats per minute (bpm).
Heart rate was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept.
Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
|
Days 1, 15, 29, 57, 78, and 85
|
LI Period; Mean Temperature (T)
Lasso di tempo: Days 1, 15, 29, 57, 78, and 85
|
Temperature was taken in participants while seated and measured in degrees celsius.
Temperature was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept.
Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
|
Days 1, 15, 29, 57, 78, and 85
|
DBW; Number of Participants With Death, Serious SAEs, Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation
Lasso di tempo: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment.
SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
|
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
DBW; Number of Participants With AEs of Special Interest
Lasso di tempo: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
|
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
DBW; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
Marked abnormality criteria are: Hemoglobin (HGB): >3 g/dL decrease from BL; Hematocrit: <0.75 * BL; Erythrocytes: <0.75 * BL; Platelets (PLT): <0.67 * LLN/>1.5 * ULN, or if BL < LLN then use <0.5 * BL and <100,000 mm^3; Leukocytes: <0.75 * LLN/ >1.25 * ULN, or if BL<LLN then use <0.8 * BL or >ULN, or if BL>ULN then use >1.2 * BL or <LLN; neutrophils+bands: <1.0 * 10^3 cells/uL; eosinophils: >0.750 * 10^3 cells/uL; basophils: > 400 mm^3; monocytes: >2000 mm^3; lymphocytes: <0.750 * 10^3 cells/uL/ >7.50 * 10^3 cells/uL.
|
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
DBW; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
Marked abnormality criteria: Alkaline phosphatase (ALP): >2* ULN, or if BL>ULN then use >3* BL; aspartate aminotransferase (AST): >3* ULN, or if BL>ULN then use >4* BL; alanine aminotransferase (ALT): >3* ULN, or if BL>ULN then use >4* BL; G-Glutamyl transferase (GGT): >2* ULN, or if BL>ULN then use >3* BL; Bilirubin: >2* ULN, or if BL>ULN then use >4* BL; blood urea nitrogen (BUN): >2* BL; creatinine: >1.5* BL
|
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
DBW; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
Marked abnormality criteria: Sodium (Na): <0.95*LLN/ >1.05*ULN, or if BL<LLN then use <0.95*
BL or >ULN, or if BL>ULN then use>1.05*
BL or <LLN; potassium (K): <0.9* LLN/>1.1*ULN, or if BL<LLN then use <0.9*
BL or >ULN, or if BL>ULN then use>1.1*
BL or <LLN; (Cl): <0.9* LLN/>1.1*
ULN, or if BL<LLN then use <0.9*
BL or >ULN, or if BL>ULN then use>1.1*
BL or <LLN; calcium (Ca): <0.8* LLN/>1.2*
ULN, or if BL<LLN then use <0.75*
BL or >ULN, or if BL>ULN then use>1.25*
BL or <LLN; phosphorous (P): <0.75* LLN/ >1.25* ULN, or if BL<LLN then use 0.67* BL or >ULN, or if BL>ULN then use>1.33*
BL or <LLN
|
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
DBW; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
MA criteria: serum glucose (Glu): <65 mg/dL/>220 mg/dL;fasting serum Glu: <0.8* LLN/>1.5*ULN,or
if BL<LLN then use 0.8*BL or >ULN,or if BL>ULN then use >2.0*BL or <LLN;total protein: <0.9*LLN/>1.1*ULN,or
if BL<LLN then use <0.9*BL or >UNL,or if BL>UNL then use >1.1*BL or <LLN; albumin: <0.9*LLN,or if BL<LLN then use <0.75 BL;uric acid: >1.5*ULN,or if BL>ULN then use >2*BL.
Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
|
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
|
DBW; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Double Blind Period
Lasso di tempo: Days 113, 141, and 169
|
Blood pressures were taken in participants while seated, just prior to study drug injection, and measured in millimeters of mercury (mmHg).
|
Days 113, 141, and 169
|
DBW Period; Mean Heart Rate (HR) During Period 2
Lasso di tempo: Days 113, 141, and 169
|
Heart Rate was taken in participants while seated, just prior to study drug injection, and measured in beats per minute (bpm)
|
Days 113, 141, and 169
|
DBW Period; Mean Temperature (T) During Period II
Lasso di tempo: Days 113, 141, and 169
|
Participants were seated and temperature taken just prior to study drug injection.
|
Days 113, 141, and 169
|
RI; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation
Lasso di tempo: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment.
SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
|
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
RI; Number of Participants With AEs of Special Interest
Lasso di tempo: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
|
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
RI; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
Marked abnormality criteria are: Hemoglobin (HGB): >3 g/dL decrease from BL; Hematocrit: <0.75 * BL; Erythrocytes: <0.75 * BL; Platelets (PLT): <0.67 * LLN/>1.5 * ULN, or if BL < LLN then use <0.5 * BL and <100,000 mm^3; Leukocytes: <0.75 * LLN/ >1.25 * ULN, or if BL<LLN then use <0.8 * BL or >ULN, or if BL>ULN then use >1.2 * BL or <LLN; neutrophils+bands: <1.0 * 10^3 cells/uL; eosinophils: >0.750 * 10^3 cells/uL; basophils: > 400 mm^3; monocytes: >2000 mm^3; lymphocytes: <0.750 * 10^3 cells/uL/ >7.50 * 10^3 cells/uL.
|
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
RI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
Marked abnormality criteria: Alkaline phosphatase (ALP): >2* ULN, or if BL>ULN then use >3* BL; aspartate aminotransferase (AST): >3* ULN, or if BL>ULN then use >4* BL; alanine aminotransferase (ALT): >3* ULN, or if BL>ULN then use >4* BL; G-Glutamyl transferase (GGT): >2* ULN, or if BL>ULN then use >3* BL; Bilirubin: >2* ULN, or if BL>ULN then use >4* BL; blood urea nitrogen (BUN): >2* BL; creatinine: >1.5* BL
|
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
RI; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
Marked abnormality criteria: Sodium (Na): <0.95*LLN/ >1.05*ULN, or if BL<LLN then use <0.95*
BL or >ULN, or if BL>ULN then use>1.05*
BL or <LLN; potassium (K): <0.9* LLN/>1.1*ULN, or if BL<LLN then use <0.9*
BL or >ULN, or if BL>ULN then use>1.1*
BL or <LLN; (Cl): <0.9* LLN/>1.1*
ULN, or if BL<LLN then use <0.9*
BL or >ULN, or if BL>ULN then use>1.1*
BL or <LLN; calcium (Ca): <0.8* LLN/>1.2*
ULN, or if BL<LLN then use <0.75*
BL or >ULN, or if BL>ULN then use>1.25*
BL or <LLN; phosphorous (P): <0.75* LLN/ >1.25* ULN, or if BL<LLN then use 0.67* BL or >ULN, or if BL>ULN then use>1.33*
BL or <LLN
|
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
RI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
Lasso di tempo: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
MA criteria: serum glucose (Glu): <65 mg/dL/>220 mg/dL;fasting serum Glu: <0.8* LLN/>1.5*ULN,or
if BL<LLN then use 0.8*BL or >ULN,or if BL>ULN then use >2.0*BL or <LLN;total protein: <0.9*LLN/>1.1*ULN,or
if BL<LLN then use <0.9*BL or >UNL,or if BL>UNL then use >1.1*BL or <LLN; albumin: <0.9*LLN,or if BL<LLN then use <0.75 BL;uric acid: >1.5*ULN,or if BL>ULN then use >2*BL.
Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
|
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
|
RI Period; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Period III
Lasso di tempo: Days 169, 197, 225, and 253
|
Days 169, 197, 225, and 253
|
|
RI Period; Mean Heart Rate (HR) During Period III
Lasso di tempo: Days 169, 197, 225, and 253
|
Days 169, 197, 225, and 253
|
|
RI Period; Mean Temperature (T) During Period III
Lasso di tempo: Days 169, 197, 225, and 253
|
Days 169, 197, 225, and 253
|
|
Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ELISA by RI Treatment Groups
Lasso di tempo: Day 197 through Day 253
|
Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body.
Cmin=minimum observed plasma concentration of single-dose abatacept.
Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ELISA.
|
Day 197 through Day 253
|
Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ECL by RI Treatment Groups
Lasso di tempo: Day 197 through Day 253
|
Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body.
Cmin=minimum observed plasma concentration of single-dose abatacept.
Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ECL.
|
Day 197 through Day 253
|
ST; Number of Participants Positive for Anti-nuclear Antibody (ANA), Anti-double Stranded DNA Antibody (dsDNA), or Rheumatoid Factor (RF) at Day 253 According to Baseline Status (Negative at Baseline or Positive at Baseline) by DBW Treatment Groups
Lasso di tempo: Baseline, Day 253
|
Venous blood was collected and tested for anti-nuclear antibodies, anti-dsDNA antibodies, and rheumatoid factor.
ANA were detected by means of immunofluorescent antibodies.
An anti-DNA radioimmunoassay was used for detection of anti-dsDNA antibodies (Diagnostic Products Corporation).
RF was measured by an immunoturbidimetric assay (Roche Tina-Quant).
Determinations of antibody or RF status were made at baseline and Day 253.
|
Baseline, Day 253
|
LTE: DAS28-CRP Mean Change From Baseline (Day 1) Over Time - All Participants Treated in LTE
Lasso di tempo: For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.
|
DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale.
DAS28-CRP has numeric thresholds defining high disease activity (> 5.1), low disease activity (≤ 3.2) and remission (< 2.6).
Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers .
Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders.
Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month.
For Period I nonresponder, study days do not represent treatment days.
Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
|
For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.
|
LTE: Percent of Participants Who Achieved Clinical Remission in the Long Term Extension - All Participants Treated in LTE
Lasso di tempo: For Period I non-responders: as of Study Day 85 and up to Study Day 1821. For ST completers: as of Study Day 253 and up to Study Day 1821
|
DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale.
Clinical remission=DAS28-CRP score<2.6.
Percent=Number of participants meeting remission divided by number of participants evaluated.
Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers .
Data are not available (NA) for the period from Day 113 to Day 253 for Period 1 non-responders.
Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month.
For Period I nonresponder, study days do not represent treatment days.
Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
|
For Period I non-responders: as of Study Day 85 and up to Study Day 1821. For ST completers: as of Study Day 253 and up to Study Day 1821
|
LTE: Percent of Participants With Low Disease Activity in Long Term Extension: All Participants Treated in LTE
Lasso di tempo: For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.
|
DAS28:continuous disease measure composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale.
Low disease activity score: ≤ 3.2.
Percent=Number of participants with Low Disease Activity divided by number of participants evaluated.
Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers .
Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders.
Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month.
For Period I nonresponder, study days do not represent treatment days.
Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
|
For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.
|
LTE: Percent of Participants With HAQ Response Over Time - All Participants Treated in LTE
Lasso di tempo: Study Days 1 (Baseline),15, 29, 57, 78, 85, 253, 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541,1625,1709,1821,1905,1989, 2073
|
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities.
The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do.
Higher scores= greater dysfunction.
A disability index (DI) was calculated by summing the worst scores in each domain and dividing by the number of domains answered.
Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ DI.
Percent=number of participants with HAQ response divided by number of participants in the analysis.
Since Period I Non-responders proceeded directly to the LTE at the end of Period I (Day 85), study days do not represent treatment days.
|
Study Days 1 (Baseline),15, 29, 57, 78, 85, 253, 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541,1625,1709,1821,1905,1989, 2073
|
LTE: Overall Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses (ECL Method) for On-Treatment Visits, Post Last Dose Visits, and Overall Study - All Participants Treated in LTE
Lasso di tempo: Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, 1989 and 28, 56, 85, 168 days post last dose in LTE
|
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using electrochemiluminescence (ECL).
The percent of participants with a positive abatacept induced immunogenicity response against cytotoxic T-lymphocyte antigen 4 (CTLA4) and possibly immunoglobulin (Ig), or against Ig and/or Junction Region was calculated by number of participants with a positive response divided by number of participants evaluated.
Overall for on-treatment includes treatment visits on Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, and 1989.
|
Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, 1989 and 28, 56, 85, 168 days post last dose in LTE
|
LTE: Number of Participants With Death, Related SAEs, SAEs Leading to Discontinuation, Related AEs, or AEs Leading to Discontinuation During Long Term Extension (LTE)
Lasso di tempo: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014), up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.
|
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment.
SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
SAEs include hospitalizations for elective surgical procedures.All deaths reported during the LTE including those that occurred > 56 days after the last dose.
Related AE or SAE defined as AE or SAE with Certain, Probable, Possible, or Missing relationship to study medication.
All participants who completed the ST period could enter the open label LTE on Day 253; LI Period 1 non-responders could directly enter the LTE.
|
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014), up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.
|
LTE: Number of Participants With AEs of Special Interest During LTE
Lasso di tempo: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014) up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.
|
AEs of special interest in LTE are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies, local injection site reaction (pre-specified AEs occurring at the site of SC injection) and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
|
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014) up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.
|
LTE: Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria During LTE
Lasso di tempo: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
|
Marked abnormality criteria are: Hemoglobin (HGB): >3 g/dL decrease from BL; Hematocrit: <0.75 * BL; Erythrocytes: <0.75 * BL; Platelets (PLT): <0.67 * LLN/>1.5 * ULN, or if BL < LLN then use <0.5 * BL and <100,000 mm^3; Leukocytes: <0.75 * LLN/ >1.25 * ULN, or if BL<LLN then use <0.8 * BL or >ULN, or if BL>ULN then use >1.2 * BL or <LLN; neutrophils+bands: <1.0 * 10^3 cells/uL; eosinophils: >0.750 * 10^3 cells/uL; basophils: > 400 mm^3; monocytes: >2000 mm^3; lymphocytes: <0.750 * 10^3 cells/uL/ >7.50 * 10^3 cells/uL.
|
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
|
LTE: Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria During LTE
Lasso di tempo: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
|
Marked abnormality criteria: Alkaline phosphatase (ALP): >2* ULN, or if BL>ULN then use >3* BL; aspartate aminotransferase (AST): >3* ULN, or if BL>ULN then use >4* BL; alanine aminotransferase (ALT): >3* ULN, or if BL>ULN then use >4* BL; G-Glutamyl transferase (GGT): >2* ULN, or if BL>ULN then use >3* BL; Bilirubin: >2* ULN, or if BL>ULN then use >4* BL; blood urea nitrogen (BUN): >2* BL; creatinine: >1.5* BL
|
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
|
LTE: Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria During LTE
Lasso di tempo: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
|
Marked abnormality criteria: Sodium (Na): <0.95*LLN/ >1.05*ULN, or if BL<LLN then use <0.95*
BL or >ULN, or if BL>ULN then use>1.05*
BL or <LLN; potassium (K): <0.9* LLN/>1.1*ULN, or if BL<LLN then use <0.9*
BL or >ULN, or if BL>ULN then use>1.1*
BL or <LLN; (Cl): <0.9* LLN/>1.1*
ULN, or if BL<LLN then use <0.9*
BL or >ULN, or if BL>ULN then use>1.1*
BL or <LLN; calcium (Ca): <0.8* LLN/>1.2*
ULN, or if BL<LLN then use <0.75*
BL or >ULN, or if BL>ULN then use>1.25*
BL or <LLN; phosphorous (P): <0.75* LLN/ >1.25* ULN, or if BL<LLN then use 0.67* BL or >ULN, or if BL>ULN then use>1.33*
BL or <LLN
|
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
|
LTE: Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria During LTE
Lasso di tempo: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
|
MA criteria: serum glucose (Glu): <65 mg/dL/>220 mg/dL;fasting serum Glu: <0.8* LLN/>1.5*ULN,or
if BL<LLN then use 0.8*BL or >ULN,or if BL>ULN then use >2.0*BL or <LLN;total protein: <0.9*LLN/>1.1*ULN,or
if BL<LLN then use <0.9*BL or >UNL,or if BL>UNL then use >1.1*BL or <LLN; albumin: <0.9*LLN,or if BL<LLN then use <0.75 BL;uric acid: >1.5*ULN,or if BL>ULN then use >2*BL.
Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
|
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
|
LTE: Mean Seated Systolic Blood Pressure (SBP) During LTE
Lasso di tempo: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261,1345, 1457,1541,1625,1709,1821,1905,1989,2073
|
During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept.
Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
|
Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261,1345, 1457,1541,1625,1709,1821,1905,1989,2073
|
LTE: Mean Seated Diastolic Blood Pressure (DBP) During LTE
Lasso di tempo: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
|
During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept.
Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
|
Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
|
LTE: Mean Heart Rate (HR) During LTE
Lasso di tempo: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
|
During LTE, heart rate was taken in participants while seated, measured in beats per minute (bpm) and was assessed at all office visits prior to SC injection of abatacept.
Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
|
Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
|
LTE: Mean Temperature (T) During LTE
Lasso di tempo: Days 337, 365, 449,533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
|
During LTE, temperature was taken in participants while seated, measured in degrees celsius and was assessed at all office visits prior to SC injection of abatacept.
Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
|
Days 337, 365, 449,533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 novembre 2007
Completamento primario (Effettivo)
1 dicembre 2008
Completamento dello studio (Effettivo)
1 febbraio 2014
Date di iscrizione allo studio
Primo inviato
20 settembre 2007
Primo inviato che soddisfa i criteri di controllo qualità
21 settembre 2007
Primo Inserito (Stima)
24 settembre 2007
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
23 aprile 2015
Ultimo aggiornamento inviato che soddisfa i criteri QC
22 aprile 2015
Ultimo verificato
1 aprile 2015
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Malattie autoimmuni
- Malattie articolari
- Malattie muscoloscheletriche
- Malattie reumatiche
- Malattie del tessuto connettivo
- Artrite
- Artrite, reumatoide
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antireumatici
- Agenti antineoplastici
- Agenti immunosoppressivi
- Fattori immunologici
- Inibitori del checkpoint immunitario
- Abatacept
Altri numeri di identificazione dello studio
- IM101-167
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Abatacept
-
Bristol-Myers SquibbCompletatoColite ulcerosaStati Uniti, Australia, India, Corea, Repubblica di, Polonia, Canada, Francia, Brasile, Messico, Porto Rico, Belgio, Svizzera, Italia, Olanda, Germania, Irlanda, Sud Africa, Regno Unito, Repubblica Ceca
-
University Medical Center GroningenBristol-Myers SquibbCompletatoSindrome di SjogrenOlanda
-
Melbourne HealthNational Health and Medical Research Council, Australia; Juvenile Diabetes Research...Attivo, non reclutanteDiabete mellito, tipo 1 | Diabete di tipo 1Australia
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletato
-
Rüdiger B. MüllerBristol-Myers SquibbCompletato
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletatoSclerosi multipla, recidivante-remittenteStati Uniti, Canada
-
Karolinska InstitutetKing's College Hospital NHS Trust; Institute of Rheumatology, PragueCompletatoDermatomiosite | PolimiositeSvezia, Cechia
-
Bristol-Myers SquibbCompletatoArtrite reumatoideStati Uniti
-
Bristol-Myers SquibbCompletato
-
Charite University, Berlin, GermanyBristol-Myers SquibbSconosciutoSpondilite anchilosanteGermania